New combo drug trial aims to control hard-to-treat prostate cancer
NCT ID NCT07244341
First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 26 times
Summary
This early-stage trial tests whether adding valemetostat to the standard drug darolutamide is safe and tolerable for men with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. About 60 adult men will receive the combination, and researchers will monitor side effects and signs that the treatment is working, such as a drop in PSA levels. The goal is to find a new way to control the disease, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Isreal Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
-
Cancer & Hematology Center
RECRUITINGGrand Rapids, Michigan, 49546-2302, United States
-
Cancer Institute Hospital of JFCR
RECRUITINGKōtoku, 135-8550, Japan
-
Carolina Urologic Research Center
RECRUITINGMyrtle Beach, South Carolina, 29572-4607, United States
-
Dana Farber Cancer Institute
RECRUITINGNewton, Massachusetts, 02467, United States
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 200032, China
-
Fudan University Shanghai Cancer Center - Xuhui District
RECRUITINGShanghai, 200032, China
-
Kobe City Med Cen Gen Hosp.
RECRUITINGKobe, 650-0047, Japan
-
Mater Misericordiae University Hospital
RECRUITINGDublin, D07 R2WY, Ireland
-
Medical College Of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226-3522, United States
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229-6028, United States
-
National Cancer Center Hospital East
RECRUITINGKashiwa-shi, 277-8577, Japan
-
Northwell Health Cancer Institute (START NY)
RECRUITINGLake Success, New York, 11042-1118, United States
-
Shanghai General Hospital
RECRUITINGShanghai, 200080, China
-
Sun Yatsen University Cancer Center
RECRUITINGGuangzhou, 510060, China
-
The First Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, 325000, China
-
Toho University Sakura Medical Center
RECRUITINGSakura-shi, 285-8741, Japan
-
University of California San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92037-0698, United States
-
Virginia Cancer Specialists (NEXT Virginia)
RECRUITINGFairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.